[
  {
    "ts": null,
    "headline": "SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal",
    "summary": "SUPN inks deal to acquire Sage Therapeutics for up to $795 million, securing rights to depression drug Zurzuvae.",
    "url": "https://finnhub.io/api/news?id=3f8dac17c4a9a3d7a6768d96791db41f86a97b685610ce68665ca1d6bf746979",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750185360,
      "headline": "SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal",
      "id": 135341090,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "SUPN inks deal to acquire Sage Therapeutics for up to $795 million, securing rights to depression drug Zurzuvae.",
      "url": "https://finnhub.io/api/news?id=3f8dac17c4a9a3d7a6768d96791db41f86a97b685610ce68665ca1d6bf746979"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Inc. stock underperforms Tuesday when compared to competitors",
    "summary": "Biogen Inc. stock underperforms Tuesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=dd08a992e71b0b2b7d198729e9d5b314c14b5a8324e30ffd37ff51cf60a0252a",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750180080,
      "headline": "Biogen Inc. stock underperforms Tuesday when compared to competitors",
      "id": 135369379,
      "image": "",
      "related": "BIIB",
      "source": "MarketWatch",
      "summary": "Biogen Inc. stock underperforms Tuesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=dd08a992e71b0b2b7d198729e9d5b314c14b5a8324e30ffd37ff51cf60a0252a"
    }
  },
  {
    "ts": null,
    "headline": "Maxion Therapeutics Appoints Dr. Stefan Härtle as Chief Development Officer",
    "summary": "Cambridge, UK, 17 June 2025 – Maxion Therapeutics (“Maxion”), a biotechnology company developing antibody-based KnotBody® drugs for ion channel and G protein coupled receptor (GPCR)-driven diseases, today announces the appointment of Dr. Stefan Härtle as Chief Development Officer, effective immediately. Stefan brings almost 20 years of pharmaceutical research and development experience to Maxion, most recently serving as Head of Clinical Pharmacology at MorphoSys, which was acquired by Novartis",
    "url": "https://finnhub.io/api/news?id=3226d261de07a5bc2f138fb81f7b88ae6a65968b8080612979fc6ef6cb7de477",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750161600,
      "headline": "Maxion Therapeutics Appoints Dr. Stefan Härtle as Chief Development Officer",
      "id": 135326594,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Cambridge, UK, 17 June 2025 – Maxion Therapeutics (“Maxion”), a biotechnology company developing antibody-based KnotBody® drugs for ion channel and G protein coupled receptor (GPCR)-driven diseases, today announces the appointment of Dr. Stefan Härtle as Chief Development Officer, effective immediately. Stefan brings almost 20 years of pharmaceutical research and development experience to Maxion, most recently serving as Head of Clinical Pharmacology at MorphoSys, which was acquired by Novartis",
      "url": "https://finnhub.io/api/news?id=3226d261de07a5bc2f138fb81f7b88ae6a65968b8080612979fc6ef6cb7de477"
    }
  }
]